Legal Representation
Attorney
Timothy H. Hiebert
USPTO Deadlines
Next Deadline
714 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-07-13)
Due Date
July 13, 2027
Grace Period Ends
January 13, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 27, 2024 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Dec 5, 2021 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Nov 12, 2021 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Nov 12, 2021 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Oct 13, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jul 13, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 27, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 27, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 25, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Apr 7, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Apr 7, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Apr 7, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 23, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 22, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 21, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 21, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 2, 2020 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Oct 10, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Oct 10, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Sep 22, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Sep 19, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Sep 18, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 18, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 18, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 17, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, alzheimer's disease, parkinson's disease, huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, alzheimer's, huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, parkinson's disease, multiple sclerosis, myasthenia gravis
Class 040
Manufacture of pharmaceuticals to the order and specification of others
Class 042
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals
Class 044
Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health
Class 045
Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders
Classification
International Classes
005
040
042
044
045
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"